Sarepta Therapeutics, Inc.
215 First Street
Cambridge, MA -2142
United States
885 articles about Sarepta Therapeutics, Inc.
-
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
2/4/2021
The four winning lesson plans are now available on sharemylesson.com Lesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroom
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 30, 2021
1/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 26 individuals hired by Sarepta in January 2021.
-
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
1/13/2021
-- Alliance will assess the use of Sarepta’s proprietary gene editing technology and Genevant’s proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for an exclusive license to Genevant’s LNP technology for four neuromuscular indications -- -- Genevant may receive approximately $50 million in near-term payments and is also eligible for significant future milestones and royalties --
-
Clinical Catch-Up: January 4-8
1/11/2021
The new year began with a fairly low level of clinical trial news. Here’s a look. -
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/8/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021 at 10:00 a.m. E.T. /7:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:20 a.m. E.T. /7:20 a.m. P.T.
-
Sarepta Therapeutics announced topline results from Part 1 of Study SRP-9001-102 for its gene therapy SRP-9001 for Duchenne muscular dystrophy.
-
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
1/7/2021
-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- -- SRP-9001-treated participants showed an increase in NSAA total score compared to placebo at 48 weeks; however, the study did not achieve statistical significance on the primary functional endpoint of improvement in NSAA total score compared to placebo at 48 weeks post-treatment --
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 31, 2020
12/31/2020
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in December 2020.
-
Sarepta Therapeutics Announces Executive Management Changes
12/14/2020
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today its board of directors approved the appointments of several executive leadership positions: Ian Estepan to executive vice president and chief financial officer, Dallan Murray to senior vice president and chief commercial officer, and Louise Rodino-Klapac, Ph.D., to executive vice president and chief scientific officer, effective today.
-
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
12/7/2020
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced results from the ongoing MOMENTUM study (Study 5051-201), a global Phase 2 clinical trial, of SRP-5051, its next-generation treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
-
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
12/4/2020
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to present interim data from the MOMENTUM study,
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 30, 2020
11/30/2020
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 28 individuals hired by Sarepta in November 2020.
-
Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
11/25/2020
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, Dec. 2, 2020 at 3:30 p.m. E.T.
-
Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
11/20/2020
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has been named one of The Boston Globe’s Top Places to Work in 2020 in the large company category.
-
Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
11/5/2020
Dosing with SRP-9001 commercial-process material to proceed followingdiscussions with U.S. FDA
-
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
11/5/2020
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, reported financial results for the third quarter of 2020.
-
Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
11/2/2020
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, November 9, 2020 at 3:30 p.m. E.T.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 30, 2020
10/30/2020
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on October 30, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in October 2020.
-
Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
10/29/2020
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2020 financial results after the Nasdaq Global Market closes on Thursday, November 5, 2020. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2020 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 fo
-
Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
10/22/2020
AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system dysfunction Bo Cumbo, most recently Sarepta’s Chief Commercial Officer and Executive Vice President, appointed Chief Executive Officer and President of AavantiBio Co-founded by pioneering gene therapy researchers Barry Byrne, M.D., Ph.D., and Manuela Corti, P.T., Ph.D.,